27R Stock Overview A medical technology company, provides software solutions for cancer care in the Americas, Europe, Africa, the Asia-Pacific, and the Middle East. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
RaySearch Laboratories AB (publ) Competitors Price History & Performance
Summary of share price highs, lows and changes for RaySearch Laboratories Historical stock prices Current Share Price SEK 18.32 52 Week High SEK 18.74 52 Week Low SEK 7.59 Beta 1.34 1 Month Change 2.58% 3 Month Change 35.10% 1 Year Change 131.90% 3 Year Change 253.67% 5 Year Change 77.69% Change since IPO 57.42%
Recent News & Updates
Investor sentiment improves as stock rises 28% Nov 12
RaySearch Laboratories AB (publ) to Report First Half, 2025 Results on Aug 07, 2025 Nov 09 RaySearch Laboratories AB (publ) to Report First Half, 2025 Results on Aug 08, 2025
RaySearch Laboratories AB (publ) Announces CFO Changes Oct 25
Deputy Chief Executive Officer recently sold €165k worth of stock Aug 25 RaySearch Laboratories AB (publ) to Report Q1, 2025 Results on May 09, 2025 See more updates
Investor sentiment improves as stock rises 28% Nov 12
RaySearch Laboratories AB (publ) to Report First Half, 2025 Results on Aug 07, 2025 Nov 09 RaySearch Laboratories AB (publ) to Report First Half, 2025 Results on Aug 08, 2025
RaySearch Laboratories AB (publ) Announces CFO Changes Oct 25
Deputy Chief Executive Officer recently sold €165k worth of stock Aug 25 RaySearch Laboratories AB (publ) to Report Q1, 2025 Results on May 09, 2025
Second quarter 2024 earnings released: EPS: kr1.79 (vs kr0.32 in 2Q 2023) Aug 18
New minor risk - Share price stability Aug 16
Investor sentiment improves as stock rises 20% Aug 16
RaySearch to Present the Latest Advances in RayStation , RayCare and RayIntelligence At AAPM 2024 Jul 22
RaySearch Releases RayStation 2024B Jul 01
RaySearch Laboratories AB (publ) Releases RayCare 2024A May 31
Now 22% undervalued May 24 Raysearch Laboratories AB (Publ) Apprves Ordinary Dividend for the Year 2023
First quarter 2024 earnings released: EPS: kr1.07 (vs kr0.51 in 1Q 2023) May 19
Raysearch to Present the Latest Advances in Raystation, Raycare and Rayintelligence At Estro 2024 May 03
Full year 2023 earnings released: EPS: kr2.38 (vs kr0.69 in FY 2022) Feb 25
New major risk - Revenue and earnings growth Feb 24 RaySearch Laboratories AB (publ) Proposes an Extra Dividend for the Year Ended December 31, 2023, Payable on May 29, 2024
RaySearch Laboratories AB (publ) to Report Fiscal Year 2024 Results on Feb 14, 2025 Feb 17
RaySearch Laboratories AB (publ) Releases Raystation 2024A Dec 22
Third quarter 2023 earnings released: EPS: kr0.63 (vs kr0.29 in 3Q 2022) Nov 19 RaySearch Laboratories AB (publ) to Report Q2, 2024 Results on Aug 16, 2024
RaySearch to Showcase Latest Innovations in Raystation, RayCare and RayIntelligence to Be Presented at ASTRO 2023 Oct 01
RaySearch Laboratories AB (Publ) to Showcase the Latest Software Innovations At Astro in San Diego, California, October 1-4 Sep 29 RaySearch Laboratories AB (publ) to Report Fiscal Year 2023 Results on Feb 23, 2024
Investor sentiment improves as stock rises 16% Aug 29
Second quarter 2023 earnings released: EPS: kr0.32 (vs kr0.58 loss in 2Q 2022) Aug 27 RaySearch Laboratories AB (publ) to Report Q1, 2024 Results on May 17, 2024
RaySearch to Present the Latest Advances in Raystation, RayCare and RayIntelligence at AAPM 2023 Jul 23
RaySearch Laboratories AB (Publ) Announces the Release of the Latest Version of RayCare®, the Next Generation Oncology Information System Jul 15
New minor risk - Share price stability Jul 14
RaySearch Laboratories AB (publ) Releases Raystation 2023B Jul 13
Raysearch Laboratories AB (Publ)'s RayCare in clinical use with CyberKnife at Lausanne University Hospital (CHUV) in Switzerland Jul 12
Henrik Bergentoft Leaves the Position as CFO for Raysearch Jul 08
New minor risk - Insider selling Jun 25
Founder recently sold €3.4m worth of stock Jun 23
New minor risk - Shareholder dilution Jun 17
RaySearch Laboratories AB (publ) Announce to Exhibit Latest Software Innovations for Particle Therapy and BNCT at PTCOG 2023 Jun 10
First quarter 2023 earnings released May 18
Founder recently sold €94k worth of stock Mar 20
Full year 2022 earnings released: EPS: kr0.69 (vs kr1.38 loss in FY 2021) Mar 01
RaySearch Laboratories AB (publ) to Report Fiscal Year 2022 Results on Feb 28, 2023 Feb 10 RaySearch Laboratories AB (publ) to Report Q3, 2023 Results on Nov 17, 2023
Third quarter 2022 earnings released Nov 30
High number of new directors Nov 16
Raysearch Laboratories AB (Publ) Elects Günther Mårder as New Board Member Nov 11
Second quarter 2022 earnings released Aug 30 Raysearch Laboratories AB (Publ) Appoints Henrik Bergentoft as Cfo, Effective from November 15, 2022
RaySearch Laboratories AB (publ) Launches RayStation 12A Jun 30
RaySearch to Exhibit the Latest Software Innovations for Particle Therapy at PTCOG 2022 Jun 28
RaySearch Laboratories AB (publ) Releases Latest Version of RayCare Jun 24
Founder recently sold €1.9m worth of stock Jun 07
First quarter 2022 earnings released May 19
Raysearch Laboratories AB (Publ) Announces Raystation, Rayintelligence and Raycare to Be Presented At Estro 2022 May 05
Insufficient new directors Apr 29
RaySearch Laboratories AB (publ) Announces Executive Changes Apr 06
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Feb 24
Founder recently sold €550k worth of stock Jan 02
RaySearch AB (publ) Provides Cancer Clinics with User Configurable Workflows for Radiation Therapy Dec 22
RayStation 11B Brings New Features for Adaptive Workflows, Brachytherapy, and Radiation Therapy with Ions Dec 17
Third quarter 2021 earnings released Nov 19
RaySearch Laboratories AB (publ) to Showcase Latest Innovations, RayIntelligence and RayCare at ESTRO 2021 Aug 27
Second quarter 2021 earnings released Aug 26
Insufficient new directors Aug 05
RaySearch Laboratories AB (Publ) Announces RayStation 9 Granted Regulatory Clearance in China Jul 07
Raysearch Announces the Release of A New Version of Raycare®, the Next-Generation Oncology Information System May 28 Raysearch Laboratories Announces the Release of Raystation® 11A
Raysearch Laboratories AB (Publ) Provides Earnings Guidance for 2021 May 05
RaySearch Laboratories AB (publ) Announces Royal Brisbane and Women's Hospital Treats First Patients Using the Raystation® Treatment Planning System Feb 27
Full year 2020 earnings released: kr0.26 loss per share (vs kr1.47 profit in FY 2019) Feb 25
Revenue misses expectations Feb 25 RaySearch Laboratories AB (publ) to Report First Half, 2021 Results on Aug 25, 2021
New 90-day high: €9.09 Feb 23
RaySearch Laboratories AB (publ) Announces University Medical Center Maribor in Slovenia Became the 700th Customer to Select RayStation Jan 22
New 90-day high: €8.92 Jan 22
RaySearch Receives New Order from Centre Antoine Lacassagne for RayStation in France Jan 09
RaySearch Laboratories AB (Publ) Announces the Release of the First Version of the Treatment Control System (TCS) Raycommand Jan 06
RaySearch Laboratories AB (publ) Announces Expansion of the Advanced Treatment Planning System Raystation Jan 05
New 90-day high: €8.35 Dec 31 RaySearch Laboratories AB (Publ) Launches Raystation® 10B for Brachytherapy Planning and New Gpu Monte Carlo Algorithm
RaySearch Laboratories AB (publ) Shares News of the Latest Release of Oncology Information System RayCare® Dec 24 Shareholder Returns 27R DE Healthcare Services DE Market 7D 2.6% -0.02% 0.3% 1Y 131.9% -21.0% 6.9%
See full shareholder returns
Return vs Market: 27R exceeded the German Market which returned 6.9% over the past year.
Price Volatility Is 27R's price volatile compared to industry and market? 27R volatility 27R Average Weekly Movement 7.2% Healthcare Services Industry Average Movement 6.1% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.7% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 27R's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 27R's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company RaySearch Laboratories AB (publ), a medical technology company, provides software solutions for cancer care in the Americas, Europe, Africa, the Asia-Pacific, and the Middle East. It develops and markets RayStation, a treatment planning system for radiation therapy; RayCare, an oncology information system that manages clinical activities; RayIntelligence, a cloud-based analytics system for monitoring and enhancement of cancer therapy; and RayCommand, a treatment control system that serves as link between the treatment machine and the treatment planning and oncology information systems. The company offers RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, and electron beam radiation therapy; and µ-RayStation, a software platform for planning and evaluation in small animal irradiation research.
Show more RaySearch Laboratories AB (publ) Fundamentals Summary How do RaySearch Laboratories's earnings and revenue compare to its market cap? 27R fundamental statistics Market cap €646.07m Earnings (TTM ) €15.27m Revenue (TTM ) €101.99m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 27R income statement (TTM ) Revenue SEK 1.17b Cost of Revenue SEK 104.50m Gross Profit SEK 1.06b Other Expenses SEK 889.45m Earnings SEK 175.06m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 21, 2025
Earnings per share (EPS) 5.11 Gross Margin 91.06% Net Profit Margin 14.97% Debt/Equity Ratio 0%
How did 27R perform over the long term?
See historical performance and comparison Dividends
0.3% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/01 08:22 End of Day Share Price 2024/12/30 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources RaySearch Laboratories AB (publ) is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Kristofer Liljeberg-Svensson Carnegie Investment Bank AB Hans Mähler DNB Markets Hans Mähler Handelsbanken Capital Markets
Show 2 more analysts 
